Anu Osinusi
Overview
Explore the profile of Anu Osinusi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
6012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asselah T, Lampertico P, Aleman S, Bourliere M, Streinu-Cercel A, Bogomolov P, et al.
Liver Int
. 2024 Dec;
45(4):e16174.
PMID: 39648559
Background And Aims: The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients...
2.
Buti M, Lim Y, Chan H, Agarwal K, Marcellin P, Brunetto M, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(11-12):1573-1586.
PMID: 39327857
Background: In two phase 3 studies, tenofovir alafenamide (TAF) showed non-inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B...
3.
Sise M, Santos J, Goldman J, Tuttle K, Teixeira J, Seibert A, et al.
Clin Infect Dis
. 2024 Jun;
79(5):1172-1181.
PMID: 38913574
Background: Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient...
4.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pantea V, et al.
N Engl J Med
. 2024 Jun;
391(2):133-143.
PMID: 38842520
Background: In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label...
5.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
J Hepatol
. 2024 May;
81(4):621-629.
PMID: 38734383
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week...
6.
Jonas M, Romero R, Rosenthal P, Lin C, Verucchi G, Wen J, et al.
J Pediatr Gastroenterol Nutr
. 2024 Apr;
78(6):1342-1354.
PMID: 38644678
Background: The safety and efficacy of sofosbuvir-velpatasvir in children aged 3-17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated. Methods: In this Phase 2, multicenter,...
7.
Humeniuk R, Juneja K, Chen S, Ellis S, Anoshchenko O, Xiao D, et al.
Clin Transl Sci
. 2023 Sep;
16(11):2276-2288.
PMID: 37688349
Intravenous remdesivir (RDV) is US Food and Drug Administration-approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS-443902, and...
8.
Chan H, Buti M, Lim Y, Agarwal K, Marcellin P, Brunetto M, et al.
Am J Gastroenterol
. 2023 Aug;
119(3):486-496.
PMID: 37561058
Introduction: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior...
9.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
N Engl J Med
. 2023 Jun;
389(1):22-32.
PMID: 37345876
Background: Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes. Methods: In this ongoing...
10.
Brown S, Katz M, Ginde A, Juneja K, Ramchandani M, Schiffer J, et al.
Infect Dis Ther
. 2023 Apr;
12(4):1189-1203.
PMID: 37074613
Introduction: In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients....